Thus, the addition of ATR-inhibitor to standards of care treatments, including ICB, was shown to enhance the antitumor T-cell response, rising a very specific effect of ATR-inhibitor on the immune compartment on top of its inhibitory impact on the cancer cell DNA-repair machinery. Here, ATR is linked to cancer.